Skip to main content

Table 1 Characterstics of included cases

From: Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

Characteristics

Amivantamab (N = 798)

Sex

 Female

367 (46.0%)

 Male

225 (28.2%)

 Missing

206 (25.8%)

Weight

 <50 kg

48 (6.0%)

 >100 kg

6 (0.8%)

 50–100 kg

268 (33.6%)

 Missing

476 (59.6%)

Age

 >85 year

3 (0.4%)

 18–65 year

215 (26.9%)

 65–85 year

212 (26.6%)

 Missing

368 (46.1%)

Occupations

 Consumers

69 (8.6%)

 Profession-healther

728 (91.3%)

 Missing

1 (0.1%)

Country

 US

386 (48.4%)

 China

77 (9.6%)

 France

31 (3.9%)

 Japan

25 (3.1%)

 South Korea

23 (2.9%)

 Others

256 (32%)